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(ABS). Data regarding tumour, treatment technique and 
patient-related features was collected, as well as recurrence 
and survival rates. 
Results: Median follow-up time was 35,1 months, 46 patients 
underwent HDR and 35 a PDR technique either with metal 
needles or flexible plastic catheters using a template-based 
system. 75 were suitable for guideline stratification (2 
patients lost to follow-up and 6 without complete 
information about risk factors). According to the ASTRO CS, 
47 patients were considered 'suitable', 23 'cautionary' and 5 
'unsuitable'. According to GEC-ESTRO, 60 were 'low risk', 7 
'intermediate risk' and 8 'high risk'. 69 patients were defined 
as 'acceptable' and 6 as 'not acceptable' following ABS 
recommendations. 46 of ABS 'acceptable' patients were also 
either 'suitable' or 'low risk' according to ASTRO and GEC-
ESTRO, meaning an accordance rate between guidelines on 
who to definitely treat with APBI of 67%. 6% (n=4) of patients 
with clear indication not to treat by ASTRO and/or GEC-
ESTRO fitted the 'acceptable' group criteria by ABS. No loco-
regional relapses were documented, 1 patient developed 
distant metastasis. 
Conclusions: This study shows a lack of agreement between 
the current guidelines and supports the existing evidence 
that APBI with multicatheter brachytherapy is an effective 
adjuvant treatment modality. 
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Purpose/Objective: Previous health related quality of life 
(HRQL) analyses of the PORTEC-2 trial showed that women 
treated with vaginal brachytherapy (VBT) reported 
significantly less bowel symptoms compared to those treated 
with pelvic radiotherapy (EBRT). In the PORTEC-1 trial, with 
longer follow-up more urinary symptoms and use of 
incontinence materials were reported by women who 
underwent EBRT. This analysis evaluates long-term HRQL in 
PORTEC-2, focussing on long-term bowel and urinary 
symptoms. 
Materials and Methods: In PORTEC-2 427 stage I endometrial 
cancer patients with high-intermediate risk features were 
randomized between postoperative EBRT or VBT. The HRQL 
questionnaire was completed at 6-12 month intervals and at 
7 and 10 years, and consisted of the EORTC QLQ-C30, and 
subscales for bowel and bladder symptoms from PR25 and 
OV28. At 7 and 10 years questions on comorbidities, and use 
of walking aids and incontinence pads were added. 
Longitudinal analysis was performed using linear mixed 
models and the t-test was applied when comparing HRQL 
scores at specific time points 
Results: The 7-year questionnaires were sent to 265 patients 
of whom 202 (76%) responded, and 80 of 119 (67%) at 10 
years due to on-going follow-up. Longitudinal analysis showed 
persistence of increased diarrhoea, faecal leakage and 
limitations due to bowel symptoms after EBRT (all p<0.001). 
For EBRT vs. VBT at 7-years, 8.4% vs 1.8% (p=0.056) patients 
reported quite a bit or very much diarrhoea, while this was 
10.5% vs 2.7% (p=0.031) for faecal leakage and 10.3% vs 2.7% 
(p=0.002) for limitations due to bowel symptoms. 
Furthermore, longitudinal analysis found an increased need 
to remain close to the toilet (p=0.001) and a trend for more 
urinary symptoms (p=0.064): for EBRT vs. VBT at 7-years 
38.9% vs 26.1% (p=0.077) reported quite a bit or very much 
urinary urgency, 12.9% vs 7.3% (p=0.079) sleep deprivation 
due to urinary urgency and 8.2% vs 6.4% (p=0.084) need to 
remain close to the toilet. No difference in the use of 
incontinence pads for EBRT vs. VBT was found at 7 years, any 
use for urine 51.1 vs 51.9% and for defecation 18.6% vs 13.5%. 
Additional analysis of previous PORTEC-1 HRQL showed that 
increased use of any incontinence material was mainly seen 
in patients treated with parallel opposed fields (72%), 
compared to 4-field technique (50.9%) and controls (40%, 
p=0.065). 
Conclusions: Up to 7 years after treatment in the PORTEC-2 
trial, patients treated with EBRT reported more bowel 
symptoms impacting on daily activities and a trend for more 
urinary symptoms, without increased use of incontinence 
pads. The increased use of incontinence pads after 15-years 
in the PORTEC-1 trial was mainly seen in patients treated 
with parallel opposing fields, while all patients in PORTEC-2 
were treated with a 4-field technique.  
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Purpose/Objective: To analyse the correlation between total 
delivered dose from external beam radiotherapy (EBRT) and 
image guided adaptive brachytherapy (IGABT) to metastatic 
nodes and individual nodal outcome in patients with locally 
advanced cervical cancer. 
Materials and Methods: A total of 140 patients enrolled in 
the Embrace study (www.embracestudy.dk) from two 
institutions were included. Treatment consisted of EBRT, 
Cisplatin and IGABT delivered in the period 2008-2013. FIGO 
stage ranged from IB-IVA with the majority being IIB or 
higher. Eighty-three patients were lymph node positive on 
FDG PET-CT and/or MRI. Lymph nodes with a SUV above 
S214                                                                                                                                         3rd ESTRO Forum 2015 
 
background or short axis > 10 mm on PET-CT were considered 
pathologic. Nodes between 5-10 mm were considered 
pathologic if the nodes had an irregular shape/border, had 
lost its architecture or were inhomogeneous. Eight patients 
were treated with lymphadenectomy prior to chemo-
radiation and did not receive a nodal boost. The remaining 75 
patients had a total number of 214 nodes boosted by EBRT 
(PTV-N) either as a simultaneous integrated boost (SIB) or as 
a sequential boost to 55-60Gy. The elective whole pelvic 
target (PTV-E) was treated to 45-50 Gy (Table 1). PTV-E was 
extended to the para-aortic region (PAN) in case of 
pathological nodes in the common iliac region or higher. 
Concomitant Cisplatin was given to 95% of the patients. MRI 
was performed 3 and 12 months after completion of 
treatment in all patients, 82/140 of the patients also had a 
PET-CT at 3 months follow-up. Additional imaging was 
performed on clinical indication. The total dose to PTV-N was 
calculated by rigidly registration of dose maps from elective 
EBRT, EBRT boost and IGABT to the planning CT scan. All 
doses were converted to EQD2 by the linear quadratic model 
(α/β = 10, repair halftime 1.5 h). 
 
Results: Pathological lymph node volume was on average 1.5 
cm3 (range 0.1-44.9) and average total dose was 62.4 Gy 
EQD2 (range 51.0-69.1). At a median follow-up time of 28 
months (range 3-64) five recurrences were diagnosed inside 
PTV-N. Each recurrent node was in a different patient. There 
was no significant impact of nodal dose for nodes receiving 
above or below 60 Gy EQD2 (Fischer's exact test, p=0.6) nor 
did we find any significance of nodal volume. (Figure 1). Two 
of the node positive patients had a new nodal recurrence 
within the PTV-E. One patient had multiple recurrences 
involving PTV-N, PTV-E, as well as distant metastases. Two of 
the node positive patients had recurrences in both PTV-E and 
outside in the PAN region. None of the 57 node negative 
patients experienced nodal recurrence in PTV-E. Nine 
patients (6%) recurred in PAN outside PTV-E without any 
other sites of recurrence. Four of these patients did not have 
nodal disease at time of diagnosis.  
Conclusions: Both micro- and macroscopic nodal control in 
locally advanced cervical cancer is high with the currently 
used treatment schedules. Recurrences are mainly located 
outside the PTV in the PAN region. Due to the limited number 
of recurrences in boosted nodes it has not been possible to 
establish a dose response relationship. 
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Purpose/Objective: Volumetric Modulated Arc Therapy 
RapidArc® (VMAT) has shown to be able to maintain a good 
toxicity profile in pelvic irradiation (PRT). We present our 
experience in treating pelvis for post-operative endometrial 
cancer (EC) with VMAT and simultaneous integrated boost 
(SIB) on vaginal cuff in patients (pts) unable to receive 
vaginal brachytherapy (VB). 
Materials and Methods: From September 2011 to December 
2013, fifty consecutive pts, submitted to hysterectomy with 
bilateral salpingo-oophorectomy and pelvic 
lymphadenectomy for EC, were candidate to PRT and VB +/- 
chemotherapy, according to stratification risk category. All 
the pts recruited refused VB for logistic problems or because 
unable or not willing to receive such treatment. After a 
specific informed consent, a dose of 54 Gy to the pelvis and 
66 Gy to the vaginal cuff in 30 fractions was delivered with 
SIB-VMAT technique. A 5 mm trans-vaginal probe and 
Magnetic Resonance Imaging were used to define vaginal 
cuff. All toxicity data were collected according to CTCAE 
v4.0; clinical outcomes were analyzed retrospectively.  
Results: Median FUP was 36 months (range, 12 to 39 months). 
According to FIGO 2009, the most representative stages 
were: IB1 (20% - 10/50), IB2 (28% - 14/50), IIA2 (16% - 8/50), IIB 
(6% - 3/50), IIIA (2% - 1/50), IIIC (28% - 14/50). The 2-year-OS 
and 2-year-LC were 96% and 100%. The 3-year-OS and LC 
were 96% and 87%. The median DFS was 25 months (range, 
12-30). No vaginal-cuff recurrence was registered. The only 
two loco-regional failures were pelvic-LNs metastases. Acute 
GI toxicity was registered as follow: G0 in 6 pts, G1 in 26 pts, 
G2 in 18 pts. No case of toxicity ≥ G3 was observed. Acute GU 
toxicity was: G0 in 5 pts, G1 in 21 pts, G2 in 24 pts. No case 
of toxicity ≥ G3 was observed. No late moderate - severe GI 
or GU toxicities were reported. A statistical correlation was 
found between acute G2 GI toxicity with Intestinal Cavity (IC) 
dose-constraints V20 Gy ≥ 30% (p-value = 0.02), V20 ≥ 40% (p 
= 0.02), V30 ≥ 30% (p = 0.004) and with IC-Dmax ≥ 45 Gy (p = 
0.001). Regarding GU assessment, the risk to develop G2 
acute toxicity is 3 times higher with adjuvant chemotherapy 
(p = 0.07).  
Conclusions: In EC pts unable to receive VB or refusing to 
receive this treatment, SIB-VMAT could be a viable 
alternative. The present analyses showed promising findings. 
Further prospective studies are advocated.  
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